Global Myasthenia Gravis Disease Market, By Diagnosis (Edrophonium Test, Blood Test, Repetitive Nerve Stimulation, Single-fiber electromyography (EMG), Others), Treatment Type (Cholinesterase Inhibitors, Corticosteroids, Immunosuppressants, Plasmapheresis, Autologous Hematopoietic Stem Cell Transplantation (HSCT), Surgery, Others), Route of Administration (Oral, Parenteral), End Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) - Industry Trends and Forecast to 2029
Market Analysis and Insights
The global market for myasthenia gravis disease is expanding rapidly and will continue to do so in the coming years. However, with the sudden outbreak of the COVID-19, the market has struggled to maintain the same growth as the research and clinical trials have slowed and there also has been a disruption in supply chain.
Data Bridge Market Research analyses that the myasthenia gravis disease market will grow at a CAGR of 10.9% during the forecast period of 2022 to 2029.
Market Definition
Myasthenia gravis is a neurological disorder marked by a failure of nerve impulse transmission that causes muscular weakness and fatigue, especially when performing repetitive activities. The condition is caused by a generalized overactivation of immune cells or is linked to the thymus gland. Arm and leg muscle weakness, double vision, and speech and chewing difficulties are all symptoms of this disease.
Myasthenia Gravis Disease Market Dynamics
Drivers
-
Surging Neuromuscular Disorders
The rise in the patients suffering from neuromuscular disease that involves cranial and spinal motor neurons, peripheral nerves, nerve plexuses, spinal nerve roots, neuromuscular junctions, and/or muscles will expand the growth rate of the treatment market. Moreover, increased level of awareness among patients regarding the disease is projected to boost the market’s growth.
Moreover, the on-going clinical trial conducted by pharmaceuticals companies to develop newer therapy are also the growth determinants which bolster the growth of the market. Also, the robust pipeline that leads to potential drugs and availability of treatment options will further enhance the growth of myasthenia gravis disease market.
Furthermore, advancement in medical technology, rising government initiatives to spread cancer awareness and growing government funding are the factors that will expand the myasthenia gravis disease market. Other factors such as increase in the demand for effective treatment procedures will positively impact the myasthenia gravis disease market's growth rate. Additionally, the people of advanced age are more susceptible to the disease and its recurrence will result in the expansion of myasthenia gravis disease market.
Opportunities
Moreover, the rise in the research and development activities and increasing investments by government and private organization will boost new opportunities for the market's growth rate.
Also, the increase in number of clinical trials for treatment of myasthenia gravis will provide beneficial opportunities for the myasthenia gravis disease market in the forecast period of 2022-2029. Also, high unmet need of current treatment and developments in healthcare technology will escalate the growth rate myasthenia gravis disease market in future.
Restraints/Challenges
However, high cost of the associated drugs and treatment and competition from off-label drugs will impede the growth rate of myasthenia gravis disease market. Additionally, the high dose combination is responsible for severe muscle cramps in myasthenia gravis patients will hinder the myasthenia gravis disease market growth. The limited availability of FDA approved drugs will further challenge the market in the forecast period mentioned above.
This myasthenia gravis disease market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on myasthenia gravis disease market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Myasthenia gravis (MG) is a kind of a long-term neuromuscular disease which basicaaly leads to varying degrees of skeletal muscle weakness. As per the estimation the majority of 36,000 people died due to this syndrome in the region of the United States in 2015.
Myasthenia gravis disease market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Covid-19 Impact on Myasthenia Gravis Disease Market
The sudden outbreak of the COVID-19 has affected the healthcare and the pharmaceutical market on a large scale. The majority of COVID-related patients are seen in medical offices, signaling a shift in the healthcare sector. COVID-19 has hampered growth, disrupted the supply chain, and caused a shift in consumer behavior. During this time, doctors were primarily focused on treating COVID patients, and myasthenia gravis patients did not receive the necessary treatment. Moreover, it prompted the implementation of strict lockdowns and quarantine regulations across the globe which further complicated the disease management and medication adherence and even further caused delays in the import and export of drugs and medicines thus affecting the market negatively. Additionally, the other research and clinical trials have slowed as a result of the increase in Covid-19 research, affecting the growth of the myasthenia gravis treatment market.
Recent Developments
- In June 2020, Argenx began public awareness campaigns for the autoimmune disease myasthenia gravis. The campaign kicked off with a virtual conference, light-up nights across the country, the launch of a patient website, and the announcement of a forthcoming documentary.
Global Myasthenia Gravis Disease Market Scope
The myasthenia gravis disease market is segmented on the basis of diagnosis, treatment type, route of administration, end users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Diagnosis
- Edrophonium Test
- Blood Test
- Repetitive Nerve Stimulation
- Single-fiber electromyography (EMG)
- Others
On the basis of diagnosis, the myasthenia gravis disease market is segmented into edrophonium test, blood test, repetitive nerve stimulation, single-fiber electromyography (EMG) and others
Treatment Type
- Cholinesterase Inhibitors
- Corticosteroids
- Immunosuppressants
- Plasmapheresis
- Autologous Hematopoietic Stem Cell Transplantation (HSCT)
- Surgery
- Others
On the basis of treatment type, the myasthenia gravis disease market is segmented into cholinesterase inhibitors, corticosteroids, immunosuppressants, plasmapheresis, autologous hematopoietic stem cell transplantation (hsct), surgery and others.
Route of Administration
- Oral
- Parenteral
On the basis of route of administration, the myasthenia gravis disease market is segmented into oral and parenteral.
End Users
- Hospitals
- Homecare
- Specialty Clinics
- Others
On the basis of end users, the myasthenia gravis disease market is segmented into hospitals, homecare, specialty clinics and others.
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
The myasthenia gravis disease market is also segmented on the basis of distribution channel into hospital pharmacy, online pharmacy and retail pharmacy.
Myasthenia Gravis Disease Market Regional Analysis/Insights
The myasthenia gravis disease market is analyzed and market size insights and trends are provided by country, diagnosis, treatment type, route of administration, end users and distribution channel as referenced above.
The countries covered in the myasthenia gravis disease market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the myasthenia gravis disease market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the increasing incidence and prevalence of myasthenia gravis in the U.S. in this region. Asia-Pacific on the other hand is projected to exhibit the highest growth rate during the forecast period due to the increasing research and development activities for treatment of myasthenia gravis in this particular region.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Myasthenia Gravis Disease Market Share Analysis
The myasthenia gravis disease market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to myasthenia gravis disease market.
Some of the major players operating in the myasthenia gravis disease market are Alexion Pharmaceuticals, Inc, Bausch Health Companies Inc., Novartis AG, Amneal Pharmaceuticals LLC, Zydus Cadila, Avadel, Dr. Reddy’s Laboratories Ltd, Fresenius Kabi AG, Endo Pharmaceuticals Inc, Amphastar Pharmaceuticals, Inc, Mylan N.V., Aurobindo Pharma, Pfizer Inc, Astellas Pharma Inc., F. Hoffmann-La Roche Ltd, Alkem Labs, and Hikma Pharmaceuticals PLC among others.
SKU-
